Sutro Biopharma is undergoing a seismic shake-up —jettisoning its CEO, half of its workforce, its lead candidate and its ...

An oral small molecule from New York-based biotech Oligomerix curbed the tangling of tau protein in the brains of mice that ...

Synthetic biology specialist GRO Biosciences started exploring strategic alternatives about six months after raising a series ...

Gilead’s Sandra Patterson has “decided to leave the company” after two years in the SVP corporate controller and chief ...

With Concentra Biosciences expanding its stock influence in Pliant Therapeutics and Acelyrin, the two biotechs have shored up ...

With its FDA-approved neurostimulator implant aimed at helping patients recover from stroke, MicroTransponder has raised $65 ...

Takeda’s revamped R&D strategy means the drugmaker’s oncology leaders are prioritizing work in tumors across thoracic, ...

Samsung is backing Alzheimer’s disease blood test developer C2N Diagnostics, with $10 million to help scale up its commercial ...

The National Institutes of Health (NIH) is continuing its grant-canceling spree, allegedly targeting dozens of research ...

The result suggests that the protein made by the gene, known as Nwd1, and other molecules it interacts with could be ...

With MeiraGTx eyeing up how to take the drug through phase 3 and onto commercialization, Hologen has stepped in. The ...

Bindman, M.D., a professor at the University of California, San Francisco (UCSF) medical school, has spent well over a decade ...